Zacks.com on MSN3d
Buy, Sell, or Hold AstraZeneca Stock? Key Tips Ahead of Q3 Earnings
Key Takeaways Zacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture ...
PMLiVE4d
AstraZeneca’s Fasenra approved by EC to treat rare inflammatory disease EGPA
AstraZeneca’s Fasenra (benralizumab) has been approved by the European Commission (EC) to treat eosinophilic granulomatosis ...
lifesciencesweden.se5d
AZ gets approval for drug targeting rare disease –it may reduce cortisone dependence
AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.